Don't Buy Arcelor Mittal NY Registry Before Checking Its Fundamentals!

We're taking a closer look at Arcelor Mittal today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 3.5% compared to 0.5% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

  • ArcelorMittal S.A., together with its subsidiaries, operates as integrated steel and mining companies in Europe, North and South America, Asia, and Africa

  • MT has an average analyst rating of buy and is -45.83% away from its mean target price of $39.82 per share

  • Its trailing 12 month price to earnings (Eps) is $-0.64 per share

  • Arcelor Mittal NY Registry has a trailing 12 month Price to Earnings (P/E) ratio of -33.5 while the S&P 500 average is 15.97

  • Its forward 12 month price to earnings (Eps) is $-0.64 per share and its forward P/E ratio is 5.4

  • MT has a Price to Earnings Growth ratio of -0.08, which shows the company is very undervalued compared to its earnings growth estimates.

  • The company has a Price to Book (P/B) ratio of 0.6 in contrast to the S&P 500's average ratio of 2.95

  • Arcelor Mittal NY Registry is part of the Basic Materials sector, which has an average P/E ratio of 8.57 and an average P/B of 1.86

  • Arcelor Mittal NY Registry has on average reported free cash flows of $2,969,000,000.00 over the last four years, during which time they have grown by an an average of 153.8%

  • MT's gross profit margins have averaged 13.0 % over the last four years, during which time they had a growth rate of 63.6 % and a coefficient of variability of 65.7 %.

At Market Interference, we believe in giving retail investors access to timely and accurate data to help inform their investment decisions. subscribe to our free newsletter today to keep track of each day's market movers!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.